Cargando…

Sintilimab, a PD-1 Inhibitor, Completely Reversed Rarely Refractory Hypofibrinogenemia in a Gastric Cancer Patient: A Case Report and Review of the Literature

While cancer is often related to hyperfibrinogenemia, it is rarely related to hypofibrinogenemia. Specifically, gastric cancer concomitant with unprovoked hypofibrinogenemia and the corresponding treatment approach have been rarely reported. We presented a case of gastric cancer in a 78-year-old Chi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Shuzhen, Dang, Qi, Yang, Yali, Liu, Yongliang, Sun, Yuping, Sun, Meili
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604326/ https://www.ncbi.nlm.nih.gov/pubmed/33194584 http://dx.doi.org/10.3389/fonc.2020.526096

Ejemplares similares

Sintilimab: A Promising Anti-Tumor PD-1 Antibody
por: Zhang, Lin, et al.
Publicado: (2020)

Angiosarcoma of the breast with hypofibrinogenemia: A rare case report and review of the literature
por: An, Ran, et al.
Publicado: (2022)

Case report: A rare case of sintilimab-induced gastric stenosis and literature review
por: Song, Kunkun, et al.
Publicado: (2023)

Case Report: A Case of Sintilimab-Induced Cystitis/Ureteritis and Review of Sintilimab-Related Adverse Events
por: Tu, Lingfang, et al.
Publicado: (2021)

Sintilimab and Chidamide for Refractory Transformed Diffuse Large B Cell Lymphoma: A Case Report and A Literature Review
por: Chen, Chao, et al.
Publicado: (2021)

Junctional Adhesion Molecule-Like Protein Promotes Tumor Progression and Metastasis via p38 Signaling Pathway in Gastric Cancer
por: Fang, Yuying, et al.
Publicado: (2021)

Clinical Study of Sintilimab as Second-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Retrospective Study
por: Nie, Caiyun, et al.
Publicado: (2021)

Case Report: Toxic epidermal necrolysis associated with sintilimab in a patient with relapsed thymic carcinoma
por: Yang, Huayu, et al.
Publicado: (2022)

Anti-PD-1 sintilimab-induced bilateral optic neuropathy in non-small cell lung cancer: A case report and literature review
por: Wang, Jian, et al.
Publicado: (2022)

Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
por: Lv, Huilai, et al.
Publicado: (2022)

Case report: Complete response of a bladder cancer patient with multiple hepatic and pelvic metastases treated by nab-paclitaxel combined with sintilimab
por: Tao, Zhu-lei, et al.
Publicado: (2022)

Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm, open-label, phase II trial
por: Guo, Honghai, et al.
Publicado: (2022)

The Efficacy and Safety of Sintilimab Combined With Nab-Paclitaxel as a Second-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer
por: Wang, Jianzheng, et al.
Publicado: (2022)

Congenital Hypofibrinogenemia: Presentation of a Rare Coagulation Disorder
por: Acevedo Viales, Karol, et al.
Publicado: (2020)

Sintilimab Combined with Lenvatinib for Advanced Intrahepatic Cholangiocarcinoma in Second-Line Setting—A Multi-Center Observational Study
por: Ding, Xiaoyan, et al.
Publicado: (2022)

Assessment of the Clinical Trials Safety Profile of PD-1/PD-L1 Inhibitors Among Patients With Cancer: An Updated Systematic Review and Meta-Analysis
por: Tian, Yuan, et al.
Publicado: (2021)

Transient hypofibrinogenemia due to allopurinol
por: Yin, ZhiQiang, et al.
Publicado: (2014)

Acquired hypofibrinogenemia: current perspectives
por: Besser, Martin W, et al.
Publicado: (2016)

Hereditary Hypofibrinogenemia with Hepatic Storage
por: Asselta, Rosanna, et al.
Publicado: (2020)

Case Report: sintilimab-induced Stevens-Johnson Syndrome in a patient with advanced lung adenocarcinoma
por: Li, Xueqin, et al.
Publicado: (2023)

Regorafenib combined with sintilimab as second-line treatment for advanced HCC patient: a case report
por: Wan, Yanzhi, et al.
Publicado: (2023)

The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study
por: Cao, Fei, et al.
Publicado: (2021)

Total knee arthroplasty in a patient with hypofibrinogenemia
por: Nacca, Christopher R., et al.
Publicado: (2015)

Risk Factors for Tigecycline-Associated Hypofibrinogenemia
por: Liu, Jia, et al.
Publicado: (2021)

Sintilimab plus Lenvatinib conversion therapy for intermediate/locally advanced hepatocellular carcinoma: A phase 2 study
por: Wang, Lijun, et al.
Publicado: (2023)

Cost-effectiveness analysis of sintilimab plus chemotherapy for advanced or metastatic esophageal squamous cell carcinoma
por: You, Maojin, et al.
Publicado: (2022)

Case report: Bullous pemphigoid associated with sintilimab therapy for pMMR/MSS colorectal cancer
por: Wang, Ting, et al.
Publicado: (2023)

Concurrent sintilimab with sequential chemoradiotherapy for unresectable, stage III non-small cell lung cancer: a retrospective study
por: Tang, Shi, et al.
Publicado: (2023)

A Lesser Known Side Effect of Tigecycline: Hypofibrinogenemia
por: Yılmaz Duran, Fulya, et al.
Publicado: (2018)

Congenital hypofibrinogenemia in pregnancy: a report of 11 cases
por: Cai, He, et al.
Publicado: (2018)

Spontaneous Intracranial Extradural Hematoma Secondary to Hypofibrinogenemia: A Rare Case Report
por: Prabhu, Santosh, et al.
Publicado: (2019)

Efficacy and Biomarker Exploration of Sintilimab Combined With Chemotherapy in the Treatment of Advanced Penile Squamous Cell Carcinoma—A Report of Two Cases
por: Mei, Xinkuan, et al.
Publicado: (2022)

Durable Response to Sintilimab and Chidamide in a Patient With Pegaspargase- and Immunotherapy-Resistant NK/T-Cell Lymphoma: Case Report and Literature Review
por: Yan, Zheng, et al.
Publicado: (2020)

Efficacy and safety of pembrolizumab versus sintilimab treatment in patients with advanced squamous lung cancer: A real-world study in China
por: Yang, Wenyu, et al.
Publicado: (2023)

Anlotinib combined with Sintilimab is win-win cooperation for primary squamous cell carcinoma of the thyroid: A case report and literature review
por: Liu, Zichang, et al.
Publicado: (2023)

Rapid Response to the Combination of Lenvatinib and Sintilimab in a Pancreatic Acinar Cell Carcinoma Patient With Elevated Alpha-Fetoprotein: A Case Report
por: Qin, Lanqun, et al.
Publicado: (2021)

Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitors Versus Regorafenib Plus PD-1 Inhibitors in Refractory Microsatellite Stable Metastatic Colorectal Cancer
por: Sun, Liying, et al.
Publicado: (2021)

Case Report: Advanced pulmonary sarcomatoid carcinoma with adrenal gland metastasis after sintilimab combined with anlotinib treatment
por: Dai, Gangyi, et al.
Publicado: (2023)

Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation
por: Cao, Jian-zhou, et al.
Publicado: (2021)

Case report: Undifferentiated sarcoma with multiple tumors involved in Lynch syndrome: Unexpected favorable outcome to sintilimab combined with chemotherapy
por: Liu, Jiaying, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5qccbr003l911mf499sksudclo